競爭分析：PI3K-AKT-mTOR抑制劑 是由出版商La Merie Publishing在2011年06月所出版的。
這份英文市場調查報告書包含100 Pages 價格從美金711起跳。
磷脂酰肌醇-3激酶（PI3K）/Akt/雷帕黴素的哺乳類標的（mTOR）的傳達路徑，在細胞成長、生存、增殖的規範上扮演重要的角色。基因突變與複製的結果，使得此路徑的異常調節對人類的各種癌症造成影響。因此，3項物質成為癌症治療的重要標的。現在受到臨床評價的第1代治療藥物為泛PI3K抑制劑，而次世代的選擇性PI3K抑制劑以2種以上的次等級為標的。
本報告，彙整PI3K-AKT-mTOR抑制劑於癌症以及其他適應上的研發計畫，並加入企業別研發產品線，由下列摘要形式闡述。
揭示資料
- 醫藥品編號
- 標的/作用機制
- 化合物等級
- 企業
- 產品種類
- 適應
- 研發階段
- 情報來源相關的附連結追加意見
索引
- 選擇性PI3K抑制劑
- PI3K、mTOR雙重抑制劑
- 其他雙重標的PI3K抑制劑
- 選擇性AKT抑制劑
- 雙重・多重標的AKT抑制劑
- 選擇性mTOR抑制劑
- 雙重mTOR1/2抑制劑
- 其他
- 各家公司的PI3K-AKT-mTOR抑制劑相關的研發產品線
- 關於La Merie
Abstract
Product description
The present Competitive Intelligence Report about PI3K-AKT-mTOR Inhibitors
provides a competitor evaluation in the field of novel molecular entities
inhibiting members of the phosphatidyl-inositol-3 kinase (PI3K) / Akt /
mammalian target of rapamycin (mTOR) pathway for treatment of cancer or
inflammatory diseases as of June 2011. Purchase of the downloadable pdf report
includes a 6-month online access to the data of the report and any updates
since the publication date. Credentials to access the database will be sent by
e-mail and allow online work with the project data to print or export an
individual report.
The phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) signaling pathway plays a critical role in the regulation of cellular
growth, survival, and proliferation. Dysregulation of this pathway, as a
result of genetic mutations and amplifications, is implicated in a variety of
human cancers. Therefore, each of the three components of the pathway alone
and in combination has emerged as a key target for the treatment of cancer.
While first generation therapeutic agents currently in clinical evaluation
preferably are pan-PI3K inhibitors, next generation selective PI3K inhibitors
are targeting one or several different subclasses.
However, only a short time ago, the paradigm existed that drugs targeted to
the four PI3K class I isoforms would be too toxic for use in cancer therapy
due to effects on physiologic signaling. Since that time, studies have
delineated the roles of these four isoforms in nonpathologic signaling as well
as their roles in cancer. An extensive effort has gone into developing agents
that inhibit one or more PI3K isoforms, e.g. alpha and beta, as well as
closely related proteins implicated in cancer. These agents have proved to be
tolerable and therapeutically beneficial in animal studies, and a number are
in clinical testing.
Numerous components of the PI3K pathway play an important role in the
expression and activation of inflammatory mediators, inflammatory cell
recruitment, immune cell function, airway remodelling and corticosteroid
insensitivity in asthma. More recently studies exploring the specific roles of
different PI3K catalytic subunit isoforms in asthma have been initiated.
Several of these have highlighted the importance of the delta isoform as a
novel target for therapeutic intervention in asthma.
Two mTOR complexes have been characterized, termed mTORC1 (mTOR complex-1) and
mTORC2. mTORC1 phosphorylates the hydrophobic motif of S6K, whereas mTORC2
phosphorylates the hydrophobic motif of Akt and SGK. The central role of mTOR
in controlling key cellular growth and survival pathways has sparked interest
in discovering mTOR inhibitors that bind to the ATP site and therefore target
both mTORC2 and mTORC1 (mTORC2 is resistant to rapamycin).
The report includes a compilation of current active projects in research and
development of PI3K-AKT-mTOR inhibitors in oncology and other indications. In
addition, the report lists company-specific R&D pipelines of PI3K-AKT-mTOR
inhibitors. Competitor projects are listed in a tabular format providing
information on:
- Drug Codes
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
- Selective PI3K Inhibitors
- Dual PI3K and mTOR Inhibitors
- Other Dual-Targeting PI3K Inhibitors
- Selective AKT Inhibitors
- Dual and Multi-Targeting AKT Inhibitors
- Selective mTOR Inhibtors
- Dual mTORC1/2 Inhibitors
- Others
- Corporate PI3K-AKT-mTOR Inhibitor R&D Pipelines
- About La Merie
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information
about the pipeline of R&D projects for targets, diseases, technologies and
companies at low prices. The information is provided in a tabular format and
fully referenced.
Table of Contents
Index
1. PI3K-AKT-mTOR Inhibitors
- Selective PI3K Inhibitors
- Dual PI3K and mTOR Inhibitors
- Other Dual-Targeting PI3K Inhibitors
- Selective AKT Inhibitors
- Dual and Multi-Targeting AKT Inhibitors
- Selective mTOR Inhibtors
- Dual mTORC1/2 Inhibitors
- Others
2. Corporate PI3K-AKT-mTOR Inhibitors R&D Pipelines
- Abbott
- Aeterna Zentaris
- Amgen
- Ariad Pharmaceuticals
- Arno Therapeutics
- Array BioPharma
- Astellas Pharma
- Astex Therapeutics
- AstraZeneca
- Avila Therapeutics
Competitor Analysis
- Bayer HealthCare Pharmaceuticals
- BioNovo
- Biotica Technology
- Celgene
- Critical Outcome Technologies
- Curis
- Eli Lilly
- Endocyte
- Enzon Pharmaceuticals
- Exelixis
- Gilead
- GlaxoSmithKline (GSK)
- Hutchison MediPharma Limited
- ICON
- Incozen Therapeutics
- Infinity Pharmaceuticals
- Inha University School of Medicine
- Intellikine
- Japan Tobacco
- Keryx Biopharmaceuticals
- MacuSight
- Merck & Co.
- Merck KGaA
- NIH
- Novartis
- Oncothyreon
- OrbusNeich
- Paloma Pharmaceuticals
- Pathway Therapeutics
- Pfizer
- PHusis Therapeutics
- Piramal Life Sciences
- Progenics Pharmaceuticals
- Roche
- S*Bio
- Samtheo Biopharma
- Sanofi
- Santen Pharmaceutical
- Semafore Pharmaceuticals
- Shanghai Inst. of Materia Medica
- Spanish National Cancer Research Centre
- SRI International
- TopoTarget
- VioQuest Pharmaceuticals
- Wilex
- Xcovery
- Yakult Honsha Co.
- Zenyaku Kogyo
